Sign In
Buy CTLT
$63.49
+0 (+0%)
At Close: Mar 14, 2025
Catalent, Inc. 2022 Q2 - Results - Earnings Call Presentation
02:05pm, Tuesday, 01'st Feb 2022 Seeking AlphaCatalent (CTLT) Q2 Earnings Top Estimates, FY22 View Up
01:04pm, Tuesday, 01'st Feb 2022
Catalent's (CTLT) robust performance across most of its segments drives its second-quarter fiscal 2022 top line.
Catalent Non-GAAP EPS of $0.90 beats by $0.07, revenue of $1.22B beats by $70M
12:06pm, Tuesday, 01'st Feb 2022 Seeking Alpha
Catalent press release (CTLT): FQ2 Non-GAAP EPS of $0.90 beats by $0.07.Revenue of $1.22B (+33.9% Y/Y) beats by $70M.Increased and tightened guidance reflects projected net
Catalent (CTLT) Surpasses Q2 Earnings and Revenue Estimates
09:59am, Tuesday, 01'st Feb 2022
Catalent (CTLT) delivered earnings and revenue surprises of 7.14% and 5.05%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Catalent's Q2 Earnings Beat Street View, Lifts FY22 Guidance
08:14am, Tuesday, 01'st Feb 2022
Catalent Inc CTLT has reported Q2 FY22 sales of $1.22 billion, +34% Y/Y as reported, or 35% in constant currency, edging out analysts' average expectation of $1.15 billion. [LIVE NOW ON YOUTUBE] Cli
Catalent Q2 2022 Earnings Preview
05:36pm, Monday, 31'st Jan 2022 Seeking Alpha
Catalent (NYSE:CTLT) is scheduled to announce Q2 earnings results on Tuesday, February 1st, before market open.The consensus EPS Estimate is $0.83 (+31.7% Y/Y) and the consensus
Catalent, Inc. Announces Second Quarter Fiscal Year 2022 Earnings Conference Webcast
08:15am, Friday, 21'st Jan 2022
SOMERSET, N.J.--(BUSINESS WIRE)--Catalent, the leading global provider of advanced delivery technologies, development, manufacturing and clinical supply solutions for drugs, biologics, cell and gene t
This Tattooed, Cowboy-Boot-Wearing Top CEO Refuses To Go Clean Cut
12:00pm, Thursday, 20'th Jan 2022 Investor''s Business Daily
John Chiminski knows he doesn''t fit the traditional image of a corporate bigwig. And the Catalent CEO is not about to change.
3 Reasons to Add Catalent (CTLT) Stock to Your Portfolio
11:30am, Thursday, 20'th Jan 2022
Catalent's (CTLT) robust facility expansion activities and a slew of strategic deals raise optimism on the stock.
Catalent (CTLT) to Advance Oral Drug Development With New Launch
09:59am, Thursday, 20'th Jan 2022
Catalent's (CTLT) Xpress Pharmaceutics service offers a quicker alternative to the traditional clinical development model, lowering the time needed to complete clinical studies.
Catalent (CTLT) Presents At J.P. Morgan Healthcare Conference
08:17pm, Wednesday, 12'th Jan 2022 Seeking AlphaCatalent, Inc. to Present at the 40th Annual J.P. Morgan Healthcare Conference
04:15pm, Monday, 03'rd Jan 2022
SOMERSET, N.J.--(BUSINESS WIRE)--Catalent, the leading global provider of advanced delivery technologies, development, manufacturing and clinical supply solutions for drugs, biologics, cell and gene t
Should You Invest Your Hard Earned Cash in Catalent (CTLT)?
12:31pm, Friday, 31'st Dec 2021 Insider Monkey
A Look Into Catalent''s Price Over Earnings
02:50pm, Thursday, 30'th Dec 2021 Benzinga
In the current session, Catalent Inc. (NYSE: CTLT ) is trading at $128.13, after a 0.1% increase. Over the past month, the stock increased by 0.34%, and in the past year, by 23.68%. With performance like this, long-term shareholders are optimistic but others are more likely to look into the price-to-earnings ratio to see if the stock might be overvalued. Assuming that all other factors are held constant, this could present itself as an opportunity for shareholders trying to capitalize on the higher share price. The stock is currently below from its 52 week high Full story available on Benzinga.com
